预防外周神经阻滞后反跳痛的干预措施:系统综述与网络Meta分析
静脉地塞米松降低反跳痛发生率的概率最高(SUCRA 0.91),被判定为明确优于对照;神经周围地塞米松和右美托咪定在延迟反跳痛和延长首次补救镇痛时间方面排名最高。证据确定性从极低到中等不等。
要点
- 静脉地塞米松是预防单次外周神经阻滞后反跳痛最有效的干预。
- 神经周围地塞米松和右美托咪定可延迟反跳痛发生并延长镇痛时间。
- 预防性阿片类药物可能劣于对照,证据确定性多为低至中等。
核心结论
- 静脉地塞米松是预防单次外周神经阻滞后反跳痛最有效的干预措施。
- 神经周围地塞米松和右美托咪定在延迟反跳痛发生和延长镇痛时间方面显示获益。
- 预防性阿片类药物可能劣于对照。
研究设计与样本
- 检索相关数据库,纳入接受外周神经阻滞手术的成人随机对照试验。
- 主要结局为反跳痛发生率;次要结局包括反跳痛时间与严重程度、首次补救镇痛时间、患者满意度、睡眠障碍及干预相关不良事件。
主要发现
- 静脉地塞米松降低反跳痛发生率的概率最高(SUCRA 0.91),被判定为明确优于对照。
- 神经周围地塞米松和神经周围右美托咪定在延迟反跳痛和延长首次补救镇痛时间方面排名最高。
- 预防性阿片类药物可能劣于对照。
- 证据确定性从极低到中等不等。
- 疼痛严重程度、患者满意度和睡眠障碍数据报告不一致,无法合并。
关键数值与推荐
- 静脉地塞米松的SUCRA为0.91,被判定为明确优于对照。
- 神经周围地塞米松和右美托咪定在延迟反跳痛和延长首次补救镇痛时间方面排名最高。
- 预防性阿片类药物可能劣于对照。
- 证据确定性范围为极低至中等。
临床怎么用
- 支持将静脉地塞米松作为预防反跳痛的一线预防性药物。
- 神经周围地塞米松或右美托咪定可用于延迟反跳痛发生和延长镇痛时间。
- 需开展 adequately powered 试验评估替代策略。
局限性
- 证据确定性从极低到中等不等。
- 疼痛严重程度、患者满意度和睡眠障碍数据报告不一致,无法合并。
- 需要 adequately powered 试验评估替代策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rebound pain after peripheral nerve block is recognised increasingly as a postoperative complication that may diminish the benefits of regional anaesthesia. We undertook a systematic review and network meta-analysis to evaluate pharmacological strategies for its prevention. METHODS: We searched relevant databases for randomised controlled trials in adults undergoing surgery with peripheral nerve blocks. The primary outcome was the incidence of rebound pain. Secondary outcomes were: timing and severity of rebound pain; time to first rescue analgesia; patient satisfaction; sleep disturbance; and intervention-related adverse effects. RESULTS: Twenty-four randomised controlled trials (2130 patients, eight interventions) were included. Intravenous dexamethasone had the highest probability of reducing rebound pain incidence (surface under the cumulative ranking curve 0.91) and was judged 'definitely superior' to control. Perineural dexamethasone and perineural dexmedetomidine ranked highest for delaying rebound pain and prolonging time to first rescue analgesia. Pre-emptive opioids were probably inferior to control. Certainty of evidence ranged from very low to moderate. Data for pain severity, patient satisfaction and sleep disturbance were reported inconsistently and could not be pooled. DISCUSSION: Intravenous dexamethasone was the most effective intervention for preventing rebound pain following single-injection peripheral nerve blocks. Perineural dexamethasone and dexmedetomidine showed benefit in delaying onset and prolonging analgesia. These findings support intravenous dexamethasone as a first-line prophylactic drug, while highlighting the need for adequately powered trials of alternative strategies. WHAT WE DID: We looked at many studies where adults had surgery using a nerve block, which is an injection to numb part of the body. We compared different medicines to see which ones helped stop “rebound pain,” which is pain that can come back strongly after the numbness wears off. We also looked at when the pain started, how long pain relief lasted and if patients needed extra pain medicine. WHY DID WE DO IT: Nerve blocks are very good at stopping pain during and just after surgery, but sometimes the pain can suddenly come back and feel worse later. This rebound pain can make recovery harder and reduce the benefits of the nerve block. We wanted to find out which medicines can help prevent this problem. WHAT WE FOUND: We found that a medicine called dexamethasone, given into a vein, worked best at reducing the chance of rebound pain. Giving similar medicines near the nerve also helped by making the pain come back later and keeping pain relief going for longer. Some other medicines, like strong painkillers given early, did not help and may even be worse than doing nothing. Overall, giving dexamethasone into a vein appears to be the best way to help prevent rebound pain after a nerve block, although more research is still needed.
引用
- Singh NP, Makkar JK, Zhang C, et al. Prophylactic interventions to prevent rebound pain after peripheral nerve block in adults: a systematic review and network meta-analysis of randomised controlled trials. Anaesthesia. 2026. PMID: 42187168. doi:10.1111/anae.70236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。